OC
AURA icon

Opal Capital’s Aura Biosciences AURA Stock Holding History

Opal Capital’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,034
Closed -$127K – 149
2025
Q4 		$127K Buy
+22,034
New +$131K 0.03% 184

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Opal Capital's AURA Position: Q1 2026 in Review

Opal Capital sold out of Aura Biosciences (AURA) in Q1 2026, closing a stake of 22,034 shares — an estimated $127K sold.

Opal Capital first reported a position in AURA in Q4 2025 and held it in 1 quarter. The position peaked at $127K in Q4 2025. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Opal Capital reported no remaining Aura Biosciences position as of Q1 2026 after selling out during the quarter.
  • Opal Capital sold 22,034 Aura Biosciences shares in Q1 2026, an estimated $127K.
  • Opal Capital first reported a position in Aura Biosciences in Q4 2025 and held it in 1 quarter.
  • Opal Capital's Aura Biosciences position peaked at $127K in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Opal Capital's 13F filing for Q1 2026, filed 18 May 2026.